GeneralConnection.com ➔ Dictionary
Dictionary Search

xenon

Synonyms

Noun

1. Xe

2. atomic number 54, chemical element, element, noble gas, inert gas, argonon

Usage
Janus Henderson reports 4.5% stake in Xenon Pharmaceuticals (XENE) filing - Stock Titan
A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash Runway - Yahoo Finance
A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase III Azetukalner Milestones And Extended Cash Runway - simplywall.st
Driehaus files Schedule 13G/A disclosing 4.87% in Xenon (XENE) - Stock Titan
The 2026 Olympus CLV-160 Resale Playbook: Pricing, Xenon Lamp Costs, and the Pentax Compatibility Trap - MSN
Xenon Pharmaceuticals: Q1 Earnings Snapshot - kare11.com
Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026 - BioSpace
Xenon Gas Market Forecast to 2035: Growth Driven by Semiconductor and Aerospace Demand - News and Statistics - IndexBox
EyeCare4Kids Partners With Xenon Ophthalmics to Expand Access to Comprehensive Vision Exams - VisionMonday.com
Xenon Pharmaceuticals (NASDAQ: XENE) shows 5.78M-share holding, 6.26% - Stock Titan
Xenon Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
The Bull Case For Xenon Pharmaceuticals (XENE) Could Change Following Positive X‑TOLE2 Data And FDA NDA Plans - simplywall.st
Xenon to Report Q1 2026 Financial Results on May 7, 2026 - Yahoo Finance
Xenon Pharmaceuticals (XENE) director exercises options, now holds 10,641 shares - Stock Titan
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus - Yahoo Finance
Xenon Pharmaceuticals Inc (XENE) Looking At a $2 Billion Opportunity Here - Yahoo Finance
Big cash raise and strong Phase 3 results headline Xenon (XENE) Q1 2026 - Stock Titan
Xenon Reports Q1 2026 Financial Results and Provides Business Update - Yahoo Finance
Did Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative? - Yahoo Finance
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Xenon Pharmaceuticals (XENE) deepens Q1 loss but amasses $1.34B cash war chest - Stock Titan
XENON PHARMACEUTICALS INC (NASDAQ:XENE) Breakout Setup Combines 9/10 Technical Strength with 9/10 Consolidation Quality - ChartMill
A seizure drug filing is next, but Xenon has 5 more Phase 3 studies running - Stock Titan
Seven new Xenon hires get stock awards priced at $56.04 - Stock Titan
May 7 after the bell: Xenon to give Q1 update, host webcast - Stock Titan
Assessing Xenon Pharmaceuticals (XENE) Valuation After New Phase 3 Azetukalner Epilepsy Data - simplywall.st
What Xenon Pharmaceuticals (XENE)'s Positive Phase 3 X-TOLE2 Epilepsy Data Means For Shareholders - simplywall.st
Is It Too Late To Consider Xenon Pharmaceuticals (XENE) After A 58% One-Year Surge? - simplywall.st
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results for Azetukalner in Focal Onset Seizures at AAN 2026 - Quiver Quantitative
Xenon Pharmaceuticals Q1 Loss Widens - Moomoo
Analysts tout market potential of Xenon’s epilepsy drug on Phase III win - Clinical Trials Arena
Xenon Pharmaceuticals Maps Path After Standout XTOL-2 - TipRanks
Xenon Pharmaceuticals (XENE) 2026 proxy details board elections and new equity plan - Stock Titan
Xenon Pharmaceuticals stock (CA98420N1050): Director exercises options for 3,500 shares - AD HOC NEWS
Xenon's Phase 3 Supports A 'Buy' Despite Its Premium (NASDAQ:XENE) - Seeking Alpha
Xenon’s seizure drug study reads out soon. Here’s what to expect - statnews.com
Xenon To Seek Approval of First-in-Class Epilepsy Drug After Exceeding Phase 3 Expectations - BioSpace
The First Xenon-Powered Everest Climb Is Coming This Spring - Climbing Magazine
Xenon phase 3 epilepsy readout 'blows away' expectations, stock soars - Fierce Biotech
Stifel sees Xenon Pharmaceuticals stock reaching $2B in peak sales - Investing.com
Xenon Pharmaceuticals’ seizure drug shows strong efficacy in late-stage trial - statnews.com
Xenon Highlights Positive Phase 3 Azetukalner Seizure Data - TipRanks
Xenon Pharmaceuticals (XENE) Climbs 31.7% as Epilepsy Treatment Moves Forward - Yahoo Finance
Xenon’s Azetukalner Confirms Phase III Efficacy Signal, Sets Up Mid-Year NDA Filing - Citeline News & Insights
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering - Yahoo Finance
Krypton/Xenon separation at room temperature in a flexible coordinative framework sorbent - Nature
Xenon Pharma’s azetukalner shows 53% seizure reduction in trial - Investing.com
Xenon (XENE) Q1 2026 Earnings Transcript - The Globe and Mail
Xenon Pharmaceuticals surges 43.6% as Phase 3 azetukalner epilepsy data beats expectations | XENE Stock News - Quiver Quantitative
Xenon Pharmaceuticals to Announce Topline Data from Phase 3 X-TOLE2 Study of Azetukalner for Focal Onset Seizures - Quiver Quantitative
Xenon Pharmaceuticals Inc. Prices Upsized Public Offering, Anticipated Gross Proceeds of Approximately $650 Million - Quiver Quantitative
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) - Yahoo Finance
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why - Yahoo Finance
Xenon tees up FDA filing after seizure med delivers 'home run' in Phase III - FirstWord Pharma
Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development - dicardiology.com
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting - Yahoo Finance
Can Xenon Gas Really Replace Traditional Acclimatization on Mount Everest? - Global Rescue
Xenon to Present at Upcoming Investor Conferences - Yahoo Finance
Xenon Pharmaceuticals (XENE) Is Down 6.7% After $650 Million Follow-On Offering And Phase 3 Epilepsy Win - Yahoo Finance
Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals Announces Proposed Public Offering - GlobeNewswire
RBC: Revolution, Xenon, Arrowhead among top takeover targets - Yahoo Finance
Xenon Pharmaceuticals stock surges 40% on positive trial data - Investing.com
Xenon to Announce Topline Results from Phase 3 X-TOLE2 - GlobeNewswire
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update - Yahoo Finance
Assessing Xenon Pharmaceuticals (XENE) Valuation After A Sharp Recent Share Price Surge - Yahoo Finance
A Look At Xenon Pharmaceuticals (XENE) Valuation After Wolfe Research’s New Favorable Coverage - Yahoo Finance
Nova release ‘X-Alps winner’ Xenon 3 - Cross Country Magazine
KOL Views Q&A: Why Xenon's azetukalner stands out in tough-to-treat focal epilepsy - FirstWord Pharma
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - The Motley Fool
Xenon to Present at Upcoming Investor Conferences - GlobeNewswire
Xenon gas does not help elite climbers - UW Homepage
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares - Yahoo Finance
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE) - FinancialContent
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data - The Motley Fool
Xenon Pharmaceuticals (XENE) boosts 2025 inducement equity plan share reserve - Stock Titan
Rab Xenon Synthetic Jacket Review - Switchback Travel
BofA raises Xenon Pharmaceuticals price target on trial success - Investing.com
Neuronal ‘off switch’ gets closer to reality - Nature
Biopharma bites: Salspera's IPO plans, plus $600M+ raises for Xenon, Dianthus - FirstWord Pharma
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for - GlobeNewswire
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE) - FinancialContent
Xenon Pharmaceuticals prices $650M public offering at $57/share - Investing.com
Xenon Pharmaceuticals Stock Jumps as Analysts Raise Price Targets - StocksToTrade
Jefferies raises Xenon Pharmaceuticals stock price target on epilepsy drug potential - Investing.com
Xenon lines up four investor conference presentations in Q2 2026 - Stock Titan
Xenon Pharmaceuticals stock reaches all-time high at 60.5 USD - Investing.com
Baird raises Xenon Pharmaceuticals price target to $97 on trial data - Investing.com
Xenon Pharmaceuticals launches $500 million stock offering - Investing.com
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference - GlobeNewswire
Xenon Pharmaceuticals Nets $707.7 Million in $57 Share Offering With Pre-Funded Warrants - TradingView
Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals stock hits 52-week high at $46.68 - Investing.com
Xenon Pharmaceuticals Announces Proposed Public Offering - Scott Coop
Biotech Xenon raises $650M in stock sale at $57 a share - Stock Titan
Xenon Pharmaceuticals to report epilepsy drug trial results Monday - Investing.com
Xenon Pharmaceuticals (XENE) sets June 2, 2026 annual shareholder meeting and April 7 record date - Stock Titan
Jefferies reiterates Xenon Pharmaceuticals stock rating on trial data - Investing.com
Xenon brings 48-month epilepsy drug data and Phase 3 results to AAN - Stock Titan
Is Xenon Pharmaceuticals (XENE) Quietly Reframing Its Epilepsy Bet Through Equity Awards and New Data? - Yahoo Finance
Foreign Language Equivalents
Foreign Language Equivalents of 'xenon'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
xebon,   xxenon,   xenom,   xenonn,   cenon,   xenn,   xeonn,   xwnon,   xennon,   xeon,   xenob,   xenin,   xemon,   xenpn,   enon,   xenno,   xneon,   xrnon,   xnon,   xeno,   xenoon,   zenon,   exnon,   xeenon
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z